Methodology
A look behind the editorial curtain - how we research, weigh, and present evidence on ketamine therapy and mental health.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
How we gather information
- PubMed and journal databases for primary literature
- NIH, NIMH, FDA, WHO, and major clinical society guidelines
- Academic medical center publications and program descriptions
- ClinicalTrials.gov for the active research landscape
How we interpret research
- Design hierarchy: RCTs and meta-analyses over open-label studies, case series, and anecdote.
- Replication: Independent replication is weighted heavily before strong claims.
- Effect size: Statistical significance alone is not enough - clinical magnitude matters.
- Risk of bias: Funding sources, attrition, blinding, and outcome selection are all considered.
- Generalizability: Trial populations are compared against the broader patient population.
How we structure content
- A Quick Answer block at the top of major pages for direct, scannable information.
- Section headings that mirror how non-specialists actually search.
- Plain language with clinical accuracy - minimal jargon, precise where it counts.
- Frequently asked questions to surface common concerns and edge cases.
- Citations to reputable, publicly accessible sources.
How we handle uncertainty
Ketamine research is moving fast. We avoid both overclaiming benefits and dismissing emerging evidence. When the field is genuinely uncertain, we describe the state of play rather than pretending consensus exists.
How we update content
Pages are reviewed on at least an annual cadence and updated sooner when significant evidence emerges, guidelines change, or regulatory status shifts. Substantive updates are dated.
Frequently asked questions
How do you decide what to publish?+
We prioritize topics where credible evidence exists or where the public is likely to encounter confusing information. We avoid speculative or sensational claims.
How do you weigh evidence?+
We weigh study design, replication, effect size, sample size, conflicts of interest, and consistency with adjacent research before drawing conclusions.
How do you handle uncertainty?+
We state it plainly. Where evidence is preliminary, mixed, or limited, the page says so rather than implying confidence we do not have.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.